Loading...
•
Sep 30, 2022
Dyne Therapeutics Q3 2022 Earnings Report
Reported financial results for the third quarter of 2022 and provided business highlights.
Key Takeaways
Dyne Therapeutics reported a net loss of $41.4 million for the third quarter of 2022. The company's cash, cash equivalents, and marketable securities were $248.1 million as of September 30, 2022, which is anticipated to fund operations through 2024. Clinical trials for DYNE-101 and DYNE-251 are underway with data anticipated in the second half of 2023.
ACHIEVE trial evaluating DYNE-101 for the treatment of myotonic dystrophy type 1 (DM1) is underway.
DELIVER trial evaluating DYNE-251 for the treatment of Duchenne muscular dystrophy (DMD) mutations amenable to exon 51 skipping, is ongoing.
FDA granted Fast Track designation for DYNE-251 in October 2022.
Dyne presented preclinical data from its DMD programs at the World Muscle Society Congress in October 2022.
Dyne Therapeutics
Dyne Therapeutics
Forward Guidance
Dyne anticipates that subsequent events and developments will cause its views to change and specifically disclaims any obligation to do so.